2023
Usefulness of podcasts to provide public education on prostate cancer genetics
Loeb S, Sanchez Nolasco T, Siu K, Byrne N, Giri V. Usefulness of podcasts to provide public education on prostate cancer genetics. Prostate Cancer And Prostatic Diseases 2023, 26: 772-777. PMID: 36681741, DOI: 10.1038/s41391-023-00648-4.Peer-Reviewed Original Research
2022
Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer
Thakker S, Loeb S, Giri V, Bjurlin M, Matulewicz R. Attitudes, Perceptions, and Use of Cancer-based Genetic Testing Among Healthy U.S. Adults and Those With Prostate or Breast/Ovarian Cancer. Urology Practice 2022, 10: 26-32. PMID: 37103438, DOI: 10.1097/upj.0000000000000352.Peer-Reviewed Original ResearchConceptsBreast/ovarian cancerHealth Information National Trends Survey 5Ovarian cancerProstate cancerGenetic testingCancer historyGenetic testing informationHistory of cancerHealthy U.S. adultsExposure of interestHealth care professionalsSelf-reported ratesEvidence-based informationPatient populationRepresentative sampleCare professionalsPatientsSecondary objectiveU.S. adultsCancerCommon sourceCategorical variablesSurvey 5Lack of awarenessCycle 4
2021
Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine.
Giri V, Shimada A, Leader A. Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine. JCO Precision Oncology 2021, 5: 1699-1708. PMID: 34778693, PMCID: PMC8585288, DOI: 10.1200/po.21.00231.Peer-Reviewed Original ResearchConceptsExact testCancer informationMultivariate logistic regression modelPopulation-based studyCross-sectional studyFisher's exact testPopulation-based sampleGenetic awarenessNational Trends SurveyNon-Hispanic whitesLogistic regression modelsPrecision medicine eraMiddle-high incomeDiverse population-based sampleCancer careModifiable factorsPersonalized cancer treatmentCancer preventionFemale genderHealth literacyCancer fatalismMedical literacyMultivariate analysisEthnic disparitiesGenetic testingBarriers and facilitators of germline genetic evaluation for prostate cancer
Loeb S, Li R, Nolasco T, Byrne N, Cheng H, Becker D, Leader A, Giri V. Barriers and facilitators of germline genetic evaluation for prostate cancer. The Prostate 2021, 81: 754-764. PMID: 34057231, DOI: 10.1002/pros.24172.Peer-Reviewed Original ResearchConceptsCoordination of careProstate cancerChronic Diseases frameworkGuideline-concordant careGermline testingMedical oncologistsPatient factorsPhysicians' knowledgePhysician educationRadiation oncologistsPractice settingsDisease frameworkThematic saturationGenetic counselingGenetic evaluationCareOncologistsRecent dataCancerConstant comparative methodInterview guidePhysiciansNumerous barriersQualitative studyInterview transcripts
2020
Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰
Loeb S, Byrne N, Walter D, Makarov D, Wise D, Becker D, Giri V. Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation✰,✰✰. Cancer Treatment And Research Communications 2020, 25: 100212. PMID: 33091732, DOI: 10.1016/j.ctarc.2020.100212.Peer-Reviewed Original ResearchConceptsGermline testingProstate cancerUrologic practicePCa family historyLocalized prostate cancerMetastatic prostate cancerFamily history criteriaDiverse practice settingsHypothetical case scenariosGermline evaluationU.S. urologistsCancer screeningOvarian cancerPractice patternsFamily historySpecific histologicPCa prognosisNational guidelinesAmerican Urological Association sectionYounger agePractice settingsTesting guidelinesHistory criteriaUrologistsGenetic counselingThe effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer
Lynch S, Handorf E, Sorice K, Blackman E, Bealin L, Giri V, Obeid E, Ragin C, Daly M. The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer. PLOS ONE 2020, 15: e0237332. PMID: 32790761, PMCID: PMC7425919, DOI: 10.1371/journal.pone.0237332.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPCa family historyHigh-risk menProbability of PCaFamily historyPCa diagnosisRisk menWhite menDigital rectal examEarly Detection ProgramClinical risk assessmentProstate cancer disparitiesProstate cancer developmentPatient risk assessmentNeighborhood socioeconomic factorsPatient-level modelsCox regressionRectal examBaseline ageCancer disparitiesPatient variablesProstate cancerHigh riskNeighborhood social environmentClinical relevanceCancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.
Giri V, Hyatt C, Leader A. Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice. Journal Of Urology 2020, 204: 1116-1118. PMID: 32926644, DOI: 10.1097/ju.0000000000001150.Peer-Reviewed Original Research
2018
Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling
Giri V, Obeid E, Hegarty S, Gross L, Bealin L, Hyatt C, Fang C, Leader A. Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. The Prostate 2018, 78: 879-888. PMID: 29655297, PMCID: PMC6047906, DOI: 10.1002/pros.23535.Peer-Reviewed Original ResearchConceptsInherited prostate cancerProstate cancerGenetic counselingGenetic testingMultivariable linear regressionFamily history dataPre-test genetic counselingHigh baseline knowledgeSyndrome criteriaGermline testingMultivariable analysisMultigene testingMedical recordsFamily historyCancer riskSubset of malesMcNemar testUncertain significanceGEM participantsHigher knowledgeMeasures of knowledgeGenetic resultsMenGT resultsBaseline knowledge
2017
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal Of Clinical Oncology 2017, 36: jco.2017.74.117. PMID: 29236593, PMCID: PMC6075860, DOI: 10.1200/jco.2017.74.1173.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancerGenetic testingMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerAggressive prostate cancerProstate cancer riskGenetic counselingMultidisciplinary consensus statementDNA mismatch repair genesExpert consensus conferenceFamilial prostate cancerHereditary prostate cancerClinical genetic testingMismatch repair genesMetastatic settingPCa managementLynch syndromeOvarian cancerBRCA2 mutationsConsensus statementFamily historyCancer riskHeterogeneous diseaseConsensus conferenceComprehensive genetic evaluation
2016
Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style
Roussi P, Miller S, Giri V, Obeid E, Wen K, Tagai E, Scarpato J, Gross L, Roy G. Effects of a randomized trial comparing standard and enhanced counseling for men at high risk of prostate cancer as a function of race and monitoring style. Journal Of Health Psychology 2016, 23: 1800-1809. PMID: 28810355, PMCID: PMC5561513, DOI: 10.1177/1359105316671188.Peer-Reviewed Original ResearchConceptsProstate cancer screeningHigh-risk menCancer screeningProstate Cancer Risk Assessment ProgramRoutine prostate cancer screeningCancer Risk Assessment ProgramHealth education sessionsCounseling visitsEnhanced counselingProstate cancerHigh riskEducation sessionsRisk assessment programPsychosocial impactCounseling conditionMenSelf-selected sampleFunction of raceSignificant subsetRiskIntrusive ideationInterventionCounselingScreeningMonitoring style
2015
Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer
Nicolas E, Arora S, Zhou Y, Serebriiskii I, Andrake M, Handorf E, Bodian D, Vockley J, Dunbrack R, Ross E, Egleston B, Hall M, Golemis E, Giri V, Daly M. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget 2015, 6: 39614-39633. PMID: 26485759, PMCID: PMC4741850, DOI: 10.18632/oncotarget.5554.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, PhytogenicCells, CulturedDNA Breaks, Double-StrandedDNA RepairEtoposideExomeFamily HealthGenetic Predisposition to DiseaseHistonesHumansINDEL MutationMaleMiddle AgedMutationPolymorphism, Single NucleotideProstatic NeoplasmsRisk AssessmentRisk FactorsSequence Analysis, DNAT-LymphocytesHigh prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort
Liu J, Parajuli S, Blackman E, Gibbs D, Ellis A, Hull A, Beck J, Giri V, Iherjirka P, Khurana J, Ragin C. High prevalence of discordant human papillomavirus and p16 oropharyngeal squamous cell carcinomas in an African American cohort. Head & Neck 2015, 38: e867-e872. PMID: 25962720, PMCID: PMC4643423, DOI: 10.1002/hed.24117.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaSquamous cell carcinomaAfrican American cohortPolymerase chain reactionAmerican cohortHPV- oropharyngeal squamous cell carcinomaHPV/p16 statusIncidence of HPVAfrican American patientsTumor RegistryCell carcinomaSCC cohortHuman papillomavirusP16 statusAmerican patientsP16 stainingTumor blocksHPVPatientsStandard immunohistochemistryTumor typesP16 negativityCohortChain reactionSurvivalLessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project
Fleisher L, Davis S, Gross L, Bagden L, Zakrzewski D, González E, Kandadai V, Rusten C, Baskett J, Obeid E, Giri V. Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project. Journal Of Cancer Education 2015, 31: 191-197. PMID: 25971432, DOI: 10.1007/s13187-015-0854-8.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramCancer Risk Assessment ProgramRisk assessment programProstate cancerProstate cancer risk assessmentRisk assessment clinicComprehensive cancer centerCommunity-based promotionCancer risk assessmentProstate riskREACH projectUnderserved menAssessment clinicCancer CenterClinic sitesUninsured menAbnormal resultsKey implementation stepsRisk menUnique demonstration projectNavigator servicesAssessment ProgramMenCancerBlack men
2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers
2013
Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men
Hughes L, Ruth K, Rebbeck T, Giri V. Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer And Prostatic Diseases 2013, 16: 308-314. PMID: 24061634, PMCID: PMC3865712, DOI: 10.1038/pcan.2013.36.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramAfrican American menHigh-risk menCC/CTProstate cancerCancer diagnosisIL-16Family historyProstate cancer screening strategiesProstate cancer risk assessmentCancer Risk Assessment ProgramIL-16 genotypesLongitudinal screening programCancer screening strategiesProstate cancer screeningTaqMan SNP genotyping assaysProstate cancer developmentPersonalized risk estimatesAfrican AmericansCancer risk assessmentGenetic variantsHazard ratioSNP genotyping assaysCancer screeningScreening programValidation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer
Chang B, Hughes L, Chen D, Gross L, Ruth K, Giri V. Validation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer. BJU International 2013, 113: e150-e156. PMID: 23937305, PMCID: PMC3830710, DOI: 10.1111/bju.12264.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramHigh-risk groupPSA levelsCaucasian manProstate cancerFamily historyProstate cancer screening strategiesProstate cancer screening studyCancer Risk Assessment ProgramBaseline PSA levelsTaqMan single nucleotide polymorphismCancer screening strategiesCancer screening studySingle nucleotide polymorphismsAfrican American ethnicityAllele carrier statusBRCA gene mutationsPotential confoundersAge 35Eligibility criteriaClinical relevanceT alleleRisk assessment programA alleleCarrier status
2012
Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection
Hughes L, Zhu F, Ross E, Gross L, Uzzo R, Chen D, Viterbo R, Rebbeck T, Giri V. Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 53-60. PMID: 22144497, PMCID: PMC3253936, DOI: 10.1158/1055-9965.epi-11-0727.Peer-Reviewed Original ResearchConceptsEarly-onset prostate cancerProstate cancer early detectionHigh-risk menCancer early detectionAfrican American menProstate cancerEarly detectionAmerican menConcordance indexClinical informationProstate cancer risk assessmentCancer diagnosisHarrell's concordance indexAfrican American raceFamilial prostate cancerUseful clinical informationCancer risk assessmentStudy criteriaLongitudinal cohortFamily historyAge 35Clinical roleCox modelEligibility criteriaAmerican race
2010
Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val
Giri V, Ruth K, Hughes L, Uzzo R, Chen D, Boorjian S, Viterbo R, Rebbeck T. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high‐risk men: effect of TMPRSS2 Met160Val. BJU International 2010, 107: 466-470. PMID: 20735386, PMCID: PMC3052292, DOI: 10.1111/j.1464-410x.2010.09522.x.Peer-Reviewed Original ResearchConceptsHigh-risk menPCa diagnosisCaucasian manElevated prostate-specific antigen concentrationPCa screeningProstate Cancer Risk Assessment ProgramProstate-specific antigen concentrationCancer Risk Assessment ProgramProspective screening cohortCancer diagnosisProspective screening programCT/TTSecond-degree relativesAfrican American menTMPRSS2-ERG fusionUnderwent biopsyScreening cohortStudy entryAA menDegree relativesScreening programBRCA1/2 mutationsSelf-identified raceCox modelGene polymorphisms
2009
Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk
Giri V, Coups E, Ruth K, Goplerud J, Raysor S, Kim T, Bagden L, Mastalski K, Zakrzewski D, Leimkuhler S, Watkins-Bruner D. Prostate Cancer Early Detection Program Recruitment Methods and Show Rates in Men at High Risk. Journal Of Urology 2009, 182: 2212-2218. PMID: 19758657, PMCID: PMC2760660, DOI: 10.1016/j.juro.2009.07.021.Peer-Reviewed Original ResearchConceptsHigh riskProstate cancerFamily historyProstate cancer screening studyProstate cancer risk assessmentProstate Cancer Risk Assessment ProgramProstate cancer family historyRecruitment methodsShow ratesCancer Risk Assessment ProgramProstate cancer screeningCancer screening studyEarly Detection ProgramCancer family historyLow socioeconomic statusBlack menCancer risk assessmentMen 35Cancer screeningLow presentation ratesBRCA1/2 mutationsRisk assessment programProgram visitsMore menParticipant demographicsEvaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population
Kaplan D, Boorjian S, Ruth K, Egleston B, Chen D, Viterbo R, Uzzo R, Buyyounouski M, Raysor S, Giri V. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population. BJU International 2009, 105: 334-337. PMID: 19709072, PMCID: PMC2809782, DOI: 10.1111/j.1464-410x.2009.08793.x.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramProstate Cancer Prevention Trial Risk CalculatorProstate cancer riskHigh-risk menProstate cancerPSA levelsRisk scoreFamily historyAfrican American menPCPT calculatorRisk calculatorCancer riskLower baseline prostate-specific antigen levelsBaseline prostate-specific antigen levelLow baseline PSA levelsProstate-specific antigen levelCancer Risk Assessment ProgramBaseline PSA levelsMedian PSA levelRisk of diagnosisBaseline risk scoreMedian risk scoreProstate cancer ratesProstate cancer diagnosisPrevious biopsy